Literature DB >> 15642437

Pharmacological intervention in the initial prodromal phase of psychosis.

Stephan Ruhrmann1, Frauke Schultze-Lutter, Wolfgang Maier, Joachim Klosterkötter.   

Abstract

Early identification and treatment of schizophrenia may alleviate the symptoms, delay the onset and improve the outcome of psychosis. Thus, detection of individuals at risk during the prodromal phase is an important task. Universal approaches to screen the general population or healthy subjects at risk have not proven possible to-date. However, clinical criteria for detecting ultra-high risk individuals have been developed for specialized settings, with their implementation in interventional studies. This article examines the rationale for early detection and intervention of psychosis, along with a review of some of the current studies. These target prevention using psychological and/or pharmacological intervention strategies have demonstrated promising results in high risk individuals. The German Research Network on Schizophrenia (GRNS) is conducting two multicenter early intervention studies; one with early psychological intervention in subjects who manifest early prodromal symptoms; with the second trial applying clinical management and pharmacological early intervention in subjects experiencing late prodromal symptoms (high risk subjects). Despite the promising results, many of the current studies have small sample sizes with study durations of a short period. The full benefits of early detection and intervention should be revealed once larger and longer studies are conducted.

Entities:  

Mesh:

Year:  2005        PMID: 15642437     DOI: 10.1016/j.eurpsy.2004.11.001

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  13 in total

1.  Prediction and prevention of schizophrenia: what has been achieved and where to go next?

Authors:  Joachim Klosterkötter; Frauke Schultze-Lutter; Andreas Bechdolf; Stephan Ruhrmann
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

2.  Ethical concerns in schizophrenia research: looking back and moving forward.

Authors:  Scott T Wilson; Barbara Stanley
Journal:  Schizophr Bull       Date:  2005-11-10       Impact factor: 9.306

3.  Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.

Authors:  Yael Piontkewitz; Michal Arad; Ina Weiner
Journal:  Schizophr Bull       Date:  2010-05-03       Impact factor: 9.306

4.  Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Authors:  Masakuni Horiguchi; Kayleen E Hannaway; Adesewa E Adelekun; Karu Jayathilake; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

5.  Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management.

Authors:  Jonathan R Stevens; Jefferson B Prince; Laura M Prager; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2014-03-13

6.  Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study.

Authors:  Tianhong Zhang; Huijun Li; Kristen A Woodberry; Larry J Seidman; Lina Zheng; Hui Li; Shanshan Zhao; Yingying Tang; Qian Guo; Xi Lu; Kaiming Zhuo; Zhenying Qian; Annabelle Chow; Chunbo Li; Kaida Jiang; Zeping Xiao; Jijun Wang
Journal:  Schizophr Res       Date:  2013-12-30       Impact factor: 4.939

7.  Indicated prevention of schizophrenia.

Authors:  Joachim Klosterkötter
Journal:  Dtsch Arztebl Int       Date:  2008-07-25       Impact factor: 5.594

8.  Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

Authors:  Urs Meyer; Erica Spoerri; Benjamin K Yee; Markus J Schwarz; Joram Feldon
Journal:  Schizophr Bull       Date:  2008-10-08       Impact factor: 9.306

9.  Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions.

Authors:  Gabriel Gerlinger; Marta Hauser; Marc De Hert; Kathleen Lacluyse; Martien Wampers; Christoph U Correll
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

10.  Emerging psychosis and the family.

Authors:  Martin Hambrecht
Journal:  ISRN Psychiatry       Date:  2012-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.